GGrantIndex
← Leaderboards

Tait D Shanafelt

Mayo Clinic Rochester

$9,008,119
Attributed
$16,330,748
Total exposure
6
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4M · FY200625
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,330,748 · 6

By mechanism

R01$12,345,676 · 4
RF1$3,354,111 · 1
K23$630,961 · 1

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Chronic Lymphocytic Leukemia

Research focus

Chronic Lymphocytic LeukemiaBaseGeneticCohortInsightMutationResistanceDisease ProgressionToxic EffectAffectFollow-UpCharacteristicsInfectionPredict Clinical OutcomeImmuneCellsBloodAccountingAmericanCell CountDisease RemissionB-LymphocytesFutureCyclophosphamide

Grant awards (26)

Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)$3,354,111
RF1 · FY2025 · AG
Outcomes for CLL patients treated with novel therapy$671,624
R01 · FY2025 · CA
Outcomes for CLL patients treated with novel therapy$596,539
R01 · FY2024 · CA
Outcomes for CLL patients treated with novel therapy$614,982
R01 · FY2023 · CA
Outcomes for CLL patients treated with novel therapy$616,831
R01 · FY2022 · CA
Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)$464,153
R01 · FY2022 · AG
Outcomes for CLL patients treated with novel therapy$705,542
R01 · FY2021 · CA
Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)$666,402
R01 · FY2021 · AG
Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)$699,156
R01 · FY2020 · AG
Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)$699,296
R01 · FY2019 · AG
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia$634,568
R01 · FY2019 · CA
Predicting clinical outcome in individuals with small CLL B cell clones$584,454
R01 · FY2019 · CA
Prevalence, etiology, and clinical implications of low count monoclonal B-cell lymphocytosis (MBL)$698,932
R01 · FY2018 · AG
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia$691,685
R01 · FY2018 · CA
Predicting clinical outcome in individuals with small CLL B cell clones$603,908
R01 · FY2018 · CA
Predicting clinical outcome in individuals with small CLL B cell clones$605,286
R01 · FY2017 · CA
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia$510,400
R01 · FY2017 · CA
Predicting clinical outcome in individuals with small CLL B cell clones$611,624
R01 · FY2016 · CA · contact PI
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia$511,603
R01 · FY2016 · CA · contact PI
Predicting clinical outcome in individuals with small CLL B cell clones$615,766
R01 · FY2015 · CA · contact PI
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia$542,925
R01 · FY2015 · CA · contact PI
The Role of Oxidative Stress in CLL B-cell Apoptosis$126,576
K23 · FY2010 · CA · contact PI
The Role of Oxidative Stress in CLL B-cell Apoptosis$126,378
K23 · FY2009 · CA · contact PI
The Role of Oxidative Stress in CLL B-cell Apoptosis$126,187
K23 · FY2008 · CA · contact PI
The Role of Oxidative Stress in CLL B-cell Apoptosis$126,000
K23 · FY2007 · CA · contact PI
The Role of Oxidative Stress in CLL B-cell Apoptosis$125,820
K23 · FY2006 · CA · contact PI